Medicenna Announces Results of Annual General and Special Meeting of Shareholders
TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”).…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
